Literature DB >> 22951831

Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation.

Gretchen L Bentz1, Julia Shackelford, Joseph S Pagano.   

Abstract

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) induces multiple signal transduction pathways during latent EBV infection via its C-terminal activating region 1 (CTAR1), CTAR2, and the less-studied CTAR3. One mechanism by which LMP1 regulates cellular activation is through the induction of protein posttranslational modifications, including phosphorylation and ubiquitination. We recently documented that LMP1 induces a third major protein modification by physically interacting with the SUMO-conjugating enzyme Ubc9 through CTAR3 and inducing the sumoylation of cellular proteins in latently infected cells. We have now identified a specific target of LMP1-induced sumoylation, interferon regulatory factor 7 (IRF7). We hypothesize that during EBV latency, LMP1 induces the sumoylation of IRF7, limiting its transcriptional activity and modulating the activation of innate immune responses. Our data show that endogenously sumoylated IRF7 is detected in latently infected EBV lymphoblastoid cell lines. LMP1 expression coincided with increased sumoylation of IRF7 in a CTAR3-dependent manner. Additional experiments show that LMP1 CTAR3-induced sumoylation regulates the expression and function of IRF7 by decreasing its turnover, increasing its nuclear retention, decreasing its DNA binding, and limiting its transcriptional activation. Finally, we identified that IRF7 is sumoylated at lysine 452. These data demonstrate that LMP1 CTAR3 does in fact function in intracellular signaling, leading to biologic effects. We propose that CTAR3 is an important signaling region of LMP1 that regulates protein function by sumoylation. We have shown specifically that LMP1 CTAR3, in cooperation with CTAR2, can limit the ability of IRF7 to induce innate immune responses by inducing the sumoylation of IRF7.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951831      PMCID: PMC3486478          DOI: 10.1128/JVI.01407-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Mechanism of action of a novel latent membrane protein-1 dominant negative.

Authors:  P Brennan; J E Floettmann; A Mehl; M Jones; M Rowe
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 2.  Structure and function of IRF-7.

Authors:  Luwen Zhang; Joseph S Pagano
Journal:  J Interferon Cytokine Res       Date:  2002-01       Impact factor: 2.607

Review 3.  Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation.

Authors:  L Zhang; J S Pagano
Journal:  Semin Cancer Biol       Date:  2001-12       Impact factor: 15.707

4.  Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.

Authors:  A Calender; M Billaud; J P Aubry; J Banchereau; M Vuillaume; G M Lenoir
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

5.  Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV).

Authors:  A Calender; M Cordier; M Billaud; G M Lenoir
Journal:  Int J Cancer       Date:  1990-10-15       Impact factor: 7.396

7.  Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation.

Authors:  W E Miller; G Mosialos; E Kieff; N Raab-Traub
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 9.  Infectious agents and cancer: criteria for a causal relation.

Authors:  Joseph S Pagano; Martin Blaser; Marie-Annick Buendia; Blossom Damania; Kamel Khalili; Nancy Raab-Traub; Bernard Roizman
Journal:  Semin Cancer Biol       Date:  2004-12       Impact factor: 15.707

10.  Cell cycle-dependent proteolysis and phosphorylation of human Mcm10.

Authors:  M Izumi; F Yatagai; F Hanaoka
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

View more
  30 in total

1.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

2.  KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation.

Authors:  Gretchen L Bentz; Anjali Bheda-Malge; Ling Wang; Julia Shackelford; Blossom Damania; Joseph S Pagano
Journal:  Virology       Date:  2013-11-08       Impact factor: 3.616

3.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

Review 4.  Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers.

Authors:  Deilson Elgui de Oliveira; Bárbara G Müller-Coan; Joseph S Pagano
Journal:  Trends Microbiol       Date:  2016-04-07       Impact factor: 17.079

5.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

6.  Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells.

Authors:  Qinyan Yin; Xia Wang; Claire Roberts; Erik K Flemington; Joseph A Lasky
Journal:  Virology       Date:  2016-04-26       Impact factor: 3.616

Review 7.  SUMO: a novel target for anti-coronavirus therapy.

Authors:  Hong-Yeoul Ryu
Journal:  Pathog Glob Health       Date:  2021-03-26       Impact factor: 2.894

8.  Potential role of viral infection and B cells as a linker between innate and adaptive immune response in systemic lupus erythematosus.

Authors:  Mohadeseh Zarei Ghobadi; Shima Izadi; Majid Teymoori-Rad; Mohammad Farahmand; Sayed-Hamidreza Mozhgani; Negar Labbaf; Fazel Shokri; Sayed Mahdi Marashi
Journal:  Immunol Res       Date:  2021-03-30       Impact factor: 2.829

9.  Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.

Authors:  Peter Garcia; Abigail Harrod; Shruti Jha; Jessica Jenkins; Alex Barnhill; Holden Lee; Merritt Thompson; Jordan Pringle Williams; James Barefield; Ashton Mckinnon; Persia Suarez; Ananya Shah; Angela J Lowrey; Gretchen L Bentz
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

Review 10.  Interplay between viruses and host sumoylation pathways.

Authors:  Roger D Everett; Chris Boutell; Benjamin G Hale
Journal:  Nat Rev Microbiol       Date:  2013-04-29       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.